ArticleCancer medicine2024

Upfront Management of Blastoid Variant Mantle Cell Lymphoma: Making the Case for 2nd/3rd-Generation Bruton Tyrosine Kinase Inhibitor-Based Therapies.

Benjamin J Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.